Developments in T Cell Based Cancer Immunotherapies:
This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects...
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Cham
Springer International Publishing
2015
|
| Ausgabe: | 1st ed. 2015 |
| Schriftenreihe: | Cancer Drug Discovery and Development
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed |
| Beschreibung: | 1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes.-8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies |
| Beschreibung: | 1 Online Ressource (XV, 305 Seiten, 26 Illustrationen in Farbe) |
| ISBN: | 9783319211671 |
| DOI: | 10.1007/978-3-319-21167-1 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046816778 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 200721s2015 |||| o||u| ||||||eng d | ||
| 020 | |a 9783319211671 |9 978-3-319-21167-1 | ||
| 024 | 7 | |a 10.1007/978-3-319-21167-1 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-319-21167-1 | ||
| 035 | |a (OCoLC)1190906870 | ||
| 035 | |a (DE-599)BVBBV046816778 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 614.5999 | |
| 084 | |a XH 3200 |0 (DE-625)152888:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Developments in T Cell Based Cancer Immunotherapies |c edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang |
| 250 | |a 1st ed. 2015 | ||
| 264 | 1 | |a Cham |b Springer International Publishing |c 2015 | |
| 300 | |a 1 Online Ressource (XV, 305 Seiten, 26 Illustrationen in Farbe) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer Drug Discovery and Development | |
| 500 | |a 1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes.-8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies | ||
| 520 | |a This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed | ||
| 650 | 4 | |a Cancer research | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Molecular biology | |
| 650 | 4 | |a Cell biology | |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a T-Lymphozyt |0 (DE-588)4127387-4 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 0 | 2 | |a T-Lymphozyt |0 (DE-588)4127387-4 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Ascierto, Paolo A. |e Sonstige |4 oth | |
| 700 | 1 | |a Stroncek, David F. |e Sonstige |4 oth | |
| 700 | 1 | |a Wang, Ena |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783319211664 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783319211688 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783319793306 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-319-21167-1 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_2015 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032225226 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-319-21167-1 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_2015 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804181626842775552 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| building | Verbundindex |
| bvnumber | BV046816778 |
| classification_rvk | XH 3200 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-319-21167-1 (OCoLC)1190906870 (DE-599)BVBBV046816778 |
| dewey-full | 614.5999 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 614 - Forensic medicine; incidence of disease |
| dewey-raw | 614.5999 |
| dewey-search | 614.5999 |
| dewey-sort | 3614.5999 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| doi_str_mv | 10.1007/978-3-319-21167-1 |
| edition | 1st ed. 2015 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04207nmm a2200589zc 4500</leader><controlfield tag="001">BV046816778</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">200721s2015 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783319211671</subfield><subfield code="9">978-3-319-21167-1</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-319-21167-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-319-21167-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1190906870</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046816778</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">614.5999</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3200</subfield><subfield code="0">(DE-625)152888:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Developments in T Cell Based Cancer Immunotherapies</subfield><subfield code="c">edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2015</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cham</subfield><subfield code="b">Springer International Publishing</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online Ressource (XV, 305 Seiten, 26 Illustrationen in Farbe)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer Drug Discovery and Development</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes.-8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular biology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cell biology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">T-Lymphozyt</subfield><subfield code="0">(DE-588)4127387-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">T-Lymphozyt</subfield><subfield code="0">(DE-588)4127387-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ascierto, Paolo A.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stroncek, David F.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Ena</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783319211664</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783319211688</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783319793306</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-319-21167-1</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_2015</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032225226</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-319-21167-1</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_2015</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046816778 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T15:00:23Z |
| indexdate | 2024-07-10T08:54:39Z |
| institution | BVB |
| isbn | 9783319211671 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032225226 |
| oclc_num | 1190906870 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online Ressource (XV, 305 Seiten, 26 Illustrationen in Farbe) |
| psigel | ZDB-2-SME ZDB-2-SME_2015 ZDB-2-SME ZDB-2-SME_2015 |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | Springer International Publishing |
| record_format | marc |
| series2 | Cancer Drug Discovery and Development |
| spelling | Developments in T Cell Based Cancer Immunotherapies edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang 1st ed. 2015 Cham Springer International Publishing 2015 1 Online Ressource (XV, 305 Seiten, 26 Illustrationen in Farbe) txt rdacontent c rdamedia cr rdacarrier Cancer Drug Discovery and Development 1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes.-8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed Cancer research Immunology Molecular biology Cell biology Immuntherapie (DE-588)4026640-0 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf T-Lymphozyt (DE-588)4127387-4 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 s Immuntherapie (DE-588)4026640-0 s T-Lymphozyt (DE-588)4127387-4 s DE-604 Ascierto, Paolo A. Sonstige oth Stroncek, David F. Sonstige oth Wang, Ena Sonstige oth Erscheint auch als Druck-Ausgabe 9783319211664 Erscheint auch als Druck-Ausgabe 9783319211688 Erscheint auch als Druck-Ausgabe 9783319793306 https://doi.org/10.1007/978-3-319-21167-1 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Developments in T Cell Based Cancer Immunotherapies Cancer research Immunology Molecular biology Cell biology Immuntherapie (DE-588)4026640-0 gnd Krebs Medizin (DE-588)4073781-0 gnd T-Lymphozyt (DE-588)4127387-4 gnd |
| subject_GND | (DE-588)4026640-0 (DE-588)4073781-0 (DE-588)4127387-4 |
| title | Developments in T Cell Based Cancer Immunotherapies |
| title_auth | Developments in T Cell Based Cancer Immunotherapies |
| title_exact_search | Developments in T Cell Based Cancer Immunotherapies |
| title_exact_search_txtP | Developments in T Cell Based Cancer Immunotherapies |
| title_full | Developments in T Cell Based Cancer Immunotherapies edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang |
| title_fullStr | Developments in T Cell Based Cancer Immunotherapies edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang |
| title_full_unstemmed | Developments in T Cell Based Cancer Immunotherapies edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang |
| title_short | Developments in T Cell Based Cancer Immunotherapies |
| title_sort | developments in t cell based cancer immunotherapies |
| topic | Cancer research Immunology Molecular biology Cell biology Immuntherapie (DE-588)4026640-0 gnd Krebs Medizin (DE-588)4073781-0 gnd T-Lymphozyt (DE-588)4127387-4 gnd |
| topic_facet | Cancer research Immunology Molecular biology Cell biology Immuntherapie Krebs Medizin T-Lymphozyt |
| url | https://doi.org/10.1007/978-3-319-21167-1 |
| work_keys_str_mv | AT asciertopaoloa developmentsintcellbasedcancerimmunotherapies AT stroncekdavidf developmentsintcellbasedcancerimmunotherapies AT wangena developmentsintcellbasedcancerimmunotherapies |